Hasta la próxima

Auto reproducción

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

0 vistas • 07/14/23
Compartir
Empotrar
administrator
administrator
Suscriptores
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

Mostrar más
0 Comentarios sort Ordenar por
Comentarios de Facebook

Hasta la próxima

Auto reproducción